A549

Lungs-Targeted Transfection Reagent Offers Safe and Effective Delivery of Biomolecules

Retrieved on: 
Thursday, August 3, 2023
DNA, CDX, Lung cancer, NCI-H23, RNA, Transfection, Malignancy, Protein, Cystic fibrosis, NCI-H226, NCI, A549, Vaccine, Antibiotics, Sulfur, Calu-3

LAS VEGAS, Aug. 2, 2023 /PRNewswire/ -- Altogen Biosystems announced the launch of a new lungs-targeted in vivo transfection reagent.

Key Points: 
  • LAS VEGAS, Aug. 2, 2023 /PRNewswire/ -- Altogen Biosystems announced the launch of a new lungs-targeted in vivo transfection reagent.
  • The transfection reagent is a non-viral complex comprising nanoparticle-sized cationic liposomes that play a crucial role in facilitating the efficient delivery of cargo biomolecules into lung cells while avoiding the activation of the immune response (transfection protocol and data are now available at altogen.com ).
  • In vivo transfection, unlike in vitro transfection which occurs in a petri dish, is the process of delivering cargo molecules into tissue.
  • When it comes to lung-targeted in vivo transfection, there are several challenges due to the organ's natural defense mechanisms, delivery efficiency, immune response, mucosal clearance, and functionality of cargo biomolecules in vivo.

Valo Therapeutics selects Exothera to develop large-scale oncolytic Adenovirus manufacturing

Retrieved on: 
Wednesday, January 11, 2023
Potyvirus, Therapy, CMC, Immunotherapy, A549, Valo, Vaccine, Infection, A549 cell, Patient, Cancer, Doe, CDMO, GMP

HELSINKI, Finland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced it has selected Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO) specialized in gene therapy, vaccines, and oncolytic viruses, to develop a large-scale manufacturing process for clinical development of its oncolytic adenovirus, VALO-D102.

Key Points: 
  • HELSINKI, Finland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced it has selected Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO) specialized in gene therapy, vaccines, and oncolytic viruses, to develop a large-scale manufacturing process for clinical development of its oncolytic adenovirus, VALO-D102.
  • ValoTx’s VALO-D102 oncolytic adenovirus is a fundamental component of the company’s proprietary PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus) immuno-oncology platform.
  • Exothera brings expertise in adenovector and A549 cells with a deep knowledge of state-of-the-art manufacturing technology and DoE-based development tools.
  • This important work with Exothera will enable us to develop a large-scale manufacturing process for VALO-D102 to support our future clinical development plans and pave the way for future commercial-scale manufacturing.”

REPEAT -- Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company

Retrieved on: 
Thursday, January 13, 2022
CDC, Vaccination, Webcast, Forward-looking statement, Technology, Degenerative disease, SPAC, SAN, Allergic rhinitis, Private Securities Litigation Reform Act, EMA, SEC, Petra, COVID-19, Plaque, Virus, RSV, Severe acute respiratory syndrome coronavirus 2, CCR3, TLR4, Death, Influenza, Pfu DNA polymerase, NASDAQ, Viral load, Calu-3, Disease, Respiratory syncytial virus, GLOBE, T helper cell, Interferon, Infection, ELISA, Immunity, A549, Rhinovirus, Risk, Eosinophil, Revelation, FDA, Omicron, Polyp, Trial of the century, Acquisition, Video game, Pharmaceutical industry, Vaccine, Online shopping

SAN DIEGO, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced it has observed significant decrease in viral load with prophylactic treatment of REVTx-99 in three independent in vitro single cell-based assay models of SARS-CoV-2 infection.

Key Points: 
  • Human primary bronchial/tracheal cells were expanded and treated with 250 nanograms per mL (ng/mL) REVTx-99 one hour prior to infection.
  • Human alveolar epithelial cells (A549, Adenocarcinomic) were treated with 250 ng/mL REVTx-99 24 hours prior to infection.
  • These studies were conducted on behalf of Revelation by a third-party contract research laboratory specializing in viral activity assays.
  • Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease.

Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company

Retrieved on: 
Tuesday, January 11, 2022
CDC, Vaccination, Webcast, Forward-looking statement, Technology, Degenerative disease, SPAC, SAN, Allergic rhinitis, Private Securities Litigation Reform Act, EMA, SEC, Petra, COVID-19, Plaque, Virus, RSV, Severe acute respiratory syndrome coronavirus 2, CCR3, TLR4, Death, Influenza, Pfu DNA polymerase, NASDAQ, Viral load, Calu-3, Disease, Respiratory syncytial virus, GLOBE, T helper cell, Interferon, Infection, ELISA, Immunity, A549, Rhinovirus, Risk, Eosinophil, Revelation, FDA, Omicron, Polyp, Trial of the century, Acquisition, Video game, Pharmaceutical industry, Vaccine, Online shopping

SAN DIEGO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced it has observed significant decrease in viral load with prophylactic treatment of REVTx-99 in three independent in vitro single cell-based assay models of SARS-CoV-2 infection.

Key Points: 
  • Human primary bronchial/tracheal cells were expanded and treated with 250 nanograms per mL (ng/mL) REVTx-99 one hour prior to infection.
  • Human alveolar epithelial cells (A549, Adenocarcinomic) were treated with 250 ng/mL REVTx-99 24 hours prior to infection.
  • These studies were conducted on behalf of Revelation by a third-party contract research laboratory specializing in viral activity assays.
  • Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease.

TYME Technologies, Inc. Announces Additional Encouraging Preclinical Data on the Effect of TYME-19 in SARS CoV-2 Infections

Retrieved on: 
Tuesday, December 14, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Method, Forward-looking statement, U.S. Securities and Exchange Commission, LinkedIn, A549 cell, Severe acute respiratory syndrome coronavirus 2, 1836 U.S. Patent Office fire, Uncertainty, RNA transfection, Company, United States Patent and Trademark Office, Membrane protein, Hematological Cancer Research Investment and Education Act, Liver disease, Nasdaq, COVID-19, Cancer, Breast, Annual report, Toxicology, Prostate, Risk, Private Securities Litigation Reform Act, Research, Safety, Patient, Knowledge, Disease, Steroid, SARS, Virus, Twitter, Alpha, Sarcoma, Patent, Pharmaceutical industry, Vaccine, Omicron, TYME, Evotec, Delta, A549, Facebook, TYME Technologies, Inc., TYME-19, TYME TECHNOLOGIES, INC., TYME-19

TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), today announced encouraging preclinical data on the effect of TYME-19 in SARS CoV-2 infections.

Key Points: 
  • TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), today announced encouraging preclinical data on the effect of TYME-19 in SARS CoV-2 infections.
  • The Company has retained virology experts at Evotec to assess the mechanisms of TYME-19.
  • In this initial preclinical study, TYME-19 was tested post-COVID-19 infection in human lung epithelial cells (A549 cells), examining changes in viral mRNA levels.
  • At certain doses, viral mRNA inhibition of up to 90% was observed with TYME-19 treatment after 72 hours of exposure.